Construction of a novel Staphylokinase (SAK) mutant with low immunogenicity and its evaluation in rhesus monkey.
The heterologous nature of SAK, which is a thrombolytic drug, elicits high titers of neutralizing antibodies, which limits its use. Here, we aimed to establish a SAK mutant with equivalent activity to the wild type but reduced antibody reactivity, which would allow for multiple injections. Biosun software was used to predict SAK antigenic epitopes, and several main epitopes were modified by gene deletion and mutation. Ten SAK mutants were constructed, and their thrombolytic activity and immunogenicity were analyzed in vitro. SAK6, with a high expression level (45%), similar thrombolysis activity, and lower antibody reaction, was chosen for in vivo analysis in rhesus monkey. In the nearly 8-month experimental period, the antibody level of the SAK6 group was significantly lower than that of the SAK group. Moreover, only 5% of SAK activity was retained, whereas 75.6% of SAK6 activity was retained after incubating with the respective antiserum. Overall, these results demonstrate that SAK6, established through comprehensive site-directed mutagenesis program, had identical thrombolysis activity to SAK, low immunogenicity, and good safety, demonstrating its great clinical potential for thrombus disease.